



**IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4,  
as amended**

**AND IN THE MATTER OF Galderma Canada Inc. (the "Respondent")**

**PANEL ORDER WITH REGARDS TO SCHEDULING**

Decided by the Hearing Panel on the basis of the written record

Date of Order: April 20, 2016

1. FURTHER to the Notice of Hearing issued on February 23, 2016;
2. AND FURTHER to the Case Management Conference held on April 8, 2016 where the panel (the "**Panel**") of the Patented Medicine Prices Review Board seized with this proceeding requested the Parties to file a schedule with all of the steps leading up to a Hearing scheduled on September 26, 27, 28 and 29, 2016;
3. AND FURTHER to the schedule submitted by the Parties on consent on April 15, 2016.

THE PANEL ORDERS THAT:

1. The schedule for the pre-hearing steps and Hearing shall be as follows:

Delivery of Board Staff's Evidence	June 13, 2016
Delivery of Galderma Canada Inc's Evidence	July 29, 2016
Delivery of Board Staff's Reply Evidence	August 8, 2016
Cross-Examinations	August 15 - 26, 2016
Pre-hearing conference (including hearing of any pre-hearing motions)	September 6 - 9, 2016
Delivery of the Parties' Initial Written Submissions and Joint Agreed Statement of Facts (if applicable)	September 19, 2016

Hearing	September 26 - 29, 2016
Delivery of Board Staff's Supplementary Written Submissions (if necessary)	October 28, 2016
Delivery of Galderma Canada Inc's Supplementary Written Submissions (if necessary)	November 14, 2016
Delivery of Board Staff's Reply Submissions (if necessary)	November 21, 2016

DATED in Ottawa, this 20th day of April, 2016.



Dr. Mitchell Levine on behalf of the Panel.